The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global RNA-Targeted Small Molecule Drugs Market Research Report 2025
Synopsis
The global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA-Targeted Small Molecule Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Targeted Small Molecule Drugs.
Report Scope
The RNA-Targeted Small Molecule Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA-Targeted Small Molecule Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA-Targeted Small Molecule Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
Segment by Application
SMA
Oncology
Lung Fibrosis
Huntington's Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecule Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for RNA-Targeted Small Molecule Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNA-Targeted Small Molecule Drugs.
Report Scope
The RNA-Targeted Small Molecule Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global RNA-Targeted Small Molecule Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the RNA-Targeted Small Molecule Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Novartis
PTC Therapeutics
Biogen
Accent Therapeutics
Anima Biotech
Arrakis Pharmaceuticals
Epics Therapeutics
Expansion Therapeutics
Gotham Therapeutics
H3 Biomedicine
Ribometrix
Skyhawk Therapeutics
STORM Therapeutics
Twentyeight-Seven Therapeutics
Segment by Type
mRNA Translation Regulation
RNA Splicing Modification
Direct RNA Targeting
Indirect RNA Targeting - Epitranscriptomics
Segment by Application
SMA
Oncology
Lung Fibrosis
Huntington's Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of RNA-Targeted Small Molecule Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 mRNA Translation Regulation
1.2.3 RNA Splicing Modification
1.2.4 Direct RNA Targeting
1.2.5 Indirect RNA Targeting - Epitranscriptomics
1.3 Market by Application
1.3.1 Global RNA-Targeted Small Molecule Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 SMA
1.3.3 Oncology
1.3.4 Lung Fibrosis
1.3.5 Huntington's Disease
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global RNA-Targeted Small Molecule Drugs Market Perspective (2019-2030)
2.2 RNA-Targeted Small Molecule Drugs Growth Trends by Region
2.2.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 RNA-Targeted Small Molecule Drugs Historic Market Size by Region (2019-2024)
2.2.3 RNA-Targeted Small Molecule Drugs Forecasted Market Size by Region (2025-2030)
2.3 RNA-Targeted Small Molecule Drugs Market Dynamics
2.3.1 RNA-Targeted Small Molecule Drugs Industry Trends
2.3.2 RNA-Targeted Small Molecule Drugs Market Drivers
2.3.3 RNA-Targeted Small Molecule Drugs Market Challenges
2.3.4 RNA-Targeted Small Molecule Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue
3.1.1 Global Top RNA-Targeted Small Molecule Drugs Players by Revenue (2019-2024)
3.1.2 Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Players (2019-2024)
3.2 Global RNA-Targeted Small Molecule Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by RNA-Targeted Small Molecule Drugs Revenue
3.4 Global RNA-Targeted Small Molecule Drugs Market Concentration Ratio
3.4.1 Global RNA-Targeted Small Molecule Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by RNA-Targeted Small Molecule Drugs Revenue in 2023
3.5 RNA-Targeted Small Molecule Drugs Key Players Head office and Area Served
3.6 Key Players RNA-Targeted Small Molecule Drugs Product Solution and Service
3.7 Date of Enter into RNA-Targeted Small Molecule Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 RNA-Targeted Small Molecule Drugs Breakdown Data by Type
4.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Type (2019-2024)
4.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Type (2025-2030)
5 RNA-Targeted Small Molecule Drugs Breakdown Data by Application
5.1 Global RNA-Targeted Small Molecule Drugs Historic Market Size by Application (2019-2024)
5.2 Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America RNA-Targeted Small Molecule Drugs Market Size (2019-2030)
6.2 North America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024)
6.4 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe RNA-Targeted Small Molecule Drugs Market Size (2019-2030)
7.2 Europe RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024)
7.4 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size (2019-2030)
8.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America RNA-Targeted Small Molecule Drugs Market Size (2019-2030)
9.2 Latin America RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024)
9.4 Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size (2019-2030)
10.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche RNA-Targeted Small Molecule Drugs Introduction
11.1.4 Roche Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis RNA-Targeted Small Molecule Drugs Introduction
11.2.4 Novartis Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 PTC Therapeutics
11.3.1 PTC Therapeutics Company Detail
11.3.2 PTC Therapeutics Business Overview
11.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.3.4 PTC Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.3.5 PTC Therapeutics Recent Development
11.4 Biogen
11.4.1 Biogen Company Detail
11.4.2 Biogen Business Overview
11.4.3 Biogen RNA-Targeted Small Molecule Drugs Introduction
11.4.4 Biogen Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Accent Therapeutics
11.5.1 Accent Therapeutics Company Detail
11.5.2 Accent Therapeutics Business Overview
11.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.5.4 Accent Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.5.5 Accent Therapeutics Recent Development
11.6 Anima Biotech
11.6.1 Anima Biotech Company Detail
11.6.2 Anima Biotech Business Overview
11.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Introduction
11.6.4 Anima Biotech Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.6.5 Anima Biotech Recent Development
11.7 Arrakis Pharmaceuticals
11.7.1 Arrakis Pharmaceuticals Company Detail
11.7.2 Arrakis Pharmaceuticals Business Overview
11.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Introduction
11.7.4 Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.7.5 Arrakis Pharmaceuticals Recent Development
11.8 Epics Therapeutics
11.8.1 Epics Therapeutics Company Detail
11.8.2 Epics Therapeutics Business Overview
11.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.8.4 Epics Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.8.5 Epics Therapeutics Recent Development
11.9 Expansion Therapeutics
11.9.1 Expansion Therapeutics Company Detail
11.9.2 Expansion Therapeutics Business Overview
11.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.9.4 Expansion Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.9.5 Expansion Therapeutics Recent Development
11.10 Gotham Therapeutics
11.10.1 Gotham Therapeutics Company Detail
11.10.2 Gotham Therapeutics Business Overview
11.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.10.4 Gotham Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.10.5 Gotham Therapeutics Recent Development
11.11 H3 Biomedicine
11.11.1 H3 Biomedicine Company Detail
11.11.2 H3 Biomedicine Business Overview
11.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Introduction
11.11.4 H3 Biomedicine Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.11.5 H3 Biomedicine Recent Development
11.12 Ribometrix
11.12.1 Ribometrix Company Detail
11.12.2 Ribometrix Business Overview
11.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Introduction
11.12.4 Ribometrix Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.12.5 Ribometrix Recent Development
11.13 Skyhawk Therapeutics
11.13.1 Skyhawk Therapeutics Company Detail
11.13.2 Skyhawk Therapeutics Business Overview
11.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.13.4 Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.13.5 Skyhawk Therapeutics Recent Development
11.14 STORM Therapeutics
11.14.1 STORM Therapeutics Company Detail
11.14.2 STORM Therapeutics Business Overview
11.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.14.4 STORM Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.14.5 STORM Therapeutics Recent Development
11.15 Twentyeight-Seven Therapeutics
11.15.1 Twentyeight-Seven Therapeutics Company Detail
11.15.2 Twentyeight-Seven Therapeutics Business Overview
11.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Introduction
11.15.4 Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024)
11.15.5 Twentyeight-Seven Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of mRNA Translation Regulation
Table 3. Key Players of RNA Splicing Modification
Table 4. Key Players of Direct RNA Targeting
Table 5. Key Players of Indirect RNA Targeting - Epitranscriptomics
Table 6. Global RNA-Targeted Small Molecule Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global RNA-Targeted Small Molecule Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2019-2024)
Table 10. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2025-2030)
Table 12. RNA-Targeted Small Molecule Drugs Market Trends
Table 13. RNA-Targeted Small Molecule Drugs Market Drivers
Table 14. RNA-Targeted Small Molecule Drugs Market Challenges
Table 15. RNA-Targeted Small Molecule Drugs Market Restraints
Table 16. Global RNA-Targeted Small Molecule Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global RNA-Targeted Small Molecule Drugs Market Share by Players (2019-2024)
Table 18. Global Top RNA-Targeted Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Targeted Small Molecule Drugs as of 2023)
Table 19. Ranking of Global Top RNA-Targeted Small Molecule Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by RNA-Targeted Small Molecule Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players RNA-Targeted Small Molecule Drugs Product Solution and Service
Table 23. Date of Enter into RNA-Targeted Small Molecule Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global RNA-Targeted Small Molecule Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. Roche Company Detail
Table 49. Roche Business Overview
Table 50. Roche RNA-Targeted Small Molecule Drugs Product
Table 51. Roche Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 52. Roche Recent Development
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis RNA-Targeted Small Molecule Drugs Product
Table 56. Novartis Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. PTC Therapeutics Company Detail
Table 59. PTC Therapeutics Business Overview
Table 60. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 61. PTC Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 62. PTC Therapeutics Recent Development
Table 63. Biogen Company Detail
Table 64. Biogen Business Overview
Table 65. Biogen RNA-Targeted Small Molecule Drugs Product
Table 66. Biogen Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 67. Biogen Recent Development
Table 68. Accent Therapeutics Company Detail
Table 69. Accent Therapeutics Business Overview
Table 70. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 71. Accent Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 72. Accent Therapeutics Recent Development
Table 73. Anima Biotech Company Detail
Table 74. Anima Biotech Business Overview
Table 75. Anima Biotech RNA-Targeted Small Molecule Drugs Product
Table 76. Anima Biotech Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 77. Anima Biotech Recent Development
Table 78. Arrakis Pharmaceuticals Company Detail
Table 79. Arrakis Pharmaceuticals Business Overview
Table 80. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product
Table 81. Arrakis Pharmaceuticals Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 82. Arrakis Pharmaceuticals Recent Development
Table 83. Epics Therapeutics Company Detail
Table 84. Epics Therapeutics Business Overview
Table 85. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 86. Epics Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 87. Epics Therapeutics Recent Development
Table 88. Expansion Therapeutics Company Detail
Table 89. Expansion Therapeutics Business Overview
Table 90. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 91. Expansion Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 92. Expansion Therapeutics Recent Development
Table 93. Gotham Therapeutics Company Detail
Table 94. Gotham Therapeutics Business Overview
Table 95. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 96. Gotham Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 97. Gotham Therapeutics Recent Development
Table 98. H3 Biomedicine Company Detail
Table 99. H3 Biomedicine Business Overview
Table 100. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product
Table 101. H3 Biomedicine Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 102. H3 Biomedicine Recent Development
Table 103. Ribometrix Company Detail
Table 104. Ribometrix Business Overview
Table 105. Ribometrix RNA-Targeted Small Molecule Drugs Product
Table 106. Ribometrix Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 107. Ribometrix Recent Development
Table 108. Skyhawk Therapeutics Company Detail
Table 109. Skyhawk Therapeutics Business Overview
Table 110. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 111. Skyhawk Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 112. Skyhawk Therapeutics Recent Development
Table 113. STORM Therapeutics Company Detail
Table 114. STORM Therapeutics Business Overview
Table 115. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 116. STORM Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 117. STORM Therapeutics Recent Development
Table 118. Twentyeight-Seven Therapeutics Company Detail
Table 119. Twentyeight-Seven Therapeutics Business Overview
Table 120. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product
Table 121. Twentyeight-Seven Therapeutics Revenue in RNA-Targeted Small Molecule Drugs Business (2019-2024) & (US$ Million)
Table 122. Twentyeight-Seven Therapeutics Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global RNA-Targeted Small Molecule Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global RNA-Targeted Small Molecule Drugs Market Share by Type: 2023 VS 2030
Figure 3. mRNA Translation Regulation Features
Figure 4. RNA Splicing Modification Features
Figure 5. Direct RNA Targeting Features
Figure 6. Indirect RNA Targeting - Epitranscriptomics Features
Figure 7. Global RNA-Targeted Small Molecule Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global RNA-Targeted Small Molecule Drugs Market Share by Application: 2023 VS 2030
Figure 9. SMA Case Studies
Figure 10. Oncology Case Studies
Figure 11. Lung Fibrosis Case Studies
Figure 12. Huntington's Disease Case Studies
Figure 13. Others Case Studies
Figure 14. RNA-Targeted Small Molecule Drugs Report Years Considered
Figure 15. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global RNA-Targeted Small Molecule Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global RNA-Targeted Small Molecule Drugs Market Share by Region: 2023 VS 2030
Figure 18. Global RNA-Targeted Small Molecule Drugs Market Share by Players in 2023
Figure 19. Global Top RNA-Targeted Small Molecule Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Targeted Small Molecule Drugs as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by RNA-Targeted Small Molecule Drugs Revenue in 2023
Figure 21. North America RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America RNA-Targeted Small Molecule Drugs Market Share by Country (2019-2030)
Figure 23. United States RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2019-2030)
Figure 27. Germany RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share by Region (2019-2030)
Figure 35. China RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America RNA-Targeted Small Molecule Drugs Market Share by Country (2019-2030)
Figure 43. Mexico RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2019-2030)
Figure 47. Turkey RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia RNA-Targeted Small Molecule Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 51. PTC Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 52. Biogen Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 53. Accent Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 54. Anima Biotech Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 55. Arrakis Pharmaceuticals Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 56. Epics Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 57. Expansion Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 58. Gotham Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 59. H3 Biomedicine Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 60. Ribometrix Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 61. Skyhawk Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 62. STORM Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 63. Twentyeight-Seven Therapeutics Revenue Growth Rate in RNA-Targeted Small Molecule Drugs Business (2019-2024)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
